BD Announces FDA 510(K) Submission Of Rapid Molecular Test To Identify Patients Carrying Staph Superbug Prior To Surgery

With the new Medicare rules regarding hospital errors, this could offer some relief with prevention and diagnosing prior to surgery.  BD 

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA), for additional claims for the BD GeneOhmTM StaphSR assay. This will be the first assay for rapid and simultaneous identification of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from patients colonized in the nasal passage.

BD Announces FDA 510(K) Submission Of Rapid Molecular Test To Identify Patients Carrying Staph Superbug Prior To Surgery